These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
17. Sunitinib, sorafenib and mTOR inhibitors in renal cancer. Radulovic S; Bjelogrlic SK J BUON; 2007 Sep; 12 Suppl 1():S151-62. PubMed ID: 17935273 [TBL] [Abstract][Full Text] [Related]
18. Targeted therapies in metastatic renal cell carcinoma: the light at the end of the tunnel. Pouessel D; Culine S Expert Rev Anticancer Ther; 2006 Dec; 6(12):1761-7. PubMed ID: 17181490 [TBL] [Abstract][Full Text] [Related]
19. Frequent dose interruptions are required for patients receiving oral kinase inhibitor therapy for advanced renal cell carcinoma. La Vine DB; Coleman TA; Davis CH; Carbonell CE; Davis WB Am J Clin Oncol; 2010 Jun; 33(3):217-20. PubMed ID: 19745694 [TBL] [Abstract][Full Text] [Related]
20. Treatment options for metastatic renal cell carcinoma: a review. Athar U; Gentile TC Can J Urol; 2008 Apr; 15(2):3954-66. PubMed ID: 18405442 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]